Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluticasone propionate - NicOx/Ocumension Therapeutics

Next Previous
Drug Profile

Fluticasone propionate - NicOx/Ocumension Therapeutics

Alternative Names: AC-155; Fluticasone ophthalmic - NicOx; fluticasone propionate nanocrystals - NicOx/Ocumension-Therapeutics; Fluticasone propionate ophthalmic - NicOx/Ocumension-Therapeutics; fluticasone propionate ophthalmic suspension 0.1% - NicOx/Ocumension-Therapeutics; NCX 4251; OT-503

Latest Information Update: 09 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aciex Therapeutics
  • Developer NicOx; Ocumension Therapeutics
  • Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Inorganic sulfur compounds; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Dry eyes

Highest Development Phases

  • Phase II Blepharitis
  • Clinical Phase Unknown Dry eyes

Most Recent Events

  • 09 Aug 2023 Chemical structure information added
  • 16 Sep 2022 Fluticasone propionate - NicOx/Ocumension Therapeutics is available for licensing in (excluding China) as of 16 Sep 2022. https://www.nicox.com/
  • 03 Jun 2022 Clinical trials in Dry eyes in France (Ophthalmic) (Nicox pipeline, June 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top